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esponsibility of InsAbstract Lumbrokinase (LK) is a group of serine proteases with strong ﬁbrinolytic and thrombolytic
activities. In clinical practice, LK can only be administered orally because of its antigenicity, immunogenicity
and potential to produce anaphylactic reactions after injection. However, many useful drugs such as
interferon, insulin, erythropoietin and interleukin have been modiﬁed with polyethylene glycol (PEG) to
prepare injectable formulations. In this study, LK was modiﬁed with methoxy PEG succinimidyl carbonate
(mPEG-SC) with molecular weights of 5000, 10,000 and 20,000 and the pegylated products were isolated
and puriﬁed using the Akta protein puriﬁcation system. The extent of pegylation was determined by HPLC.
Fibrinolytic activities of pegylated and unmodiﬁed LK were measured both in vitro against urokinase on
ﬁbrin plates and in vivo using a mouse carageenan black tail model. Optimal pegylation was obtained using
mPEG-SC5000 in a buffer pH 8.0 with a reaction time of 5 h, reaction temperature of 0 1C and LK:mPEG-
SC molar ratio of 1:25. The results show that mPEG modiﬁed LK has strong ﬁbrinolytic and thrombolytic
activities both in vitro and in vivo. It is suggested that the pegylated LK is a promising injectable
thrombolytic agent for the treatment of thrombotic diseases in clinical practice.
& 2013 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
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Thrombotic diseases are potentially fatal conditions of multi-
ple origins. Various thrombolytic enzymes, such as streptoki-
nase and urokinase, have been used in the treatment of
thrombotic diseases along with recombinant tissue plasmino-
gen activators. Lumbrokinase (LK), a group of serine pro-
teases with strong ﬁbrinolytic activity1,2, can dissolve ﬁbrin
directly or activate proﬁbrinolysin to dissolve it indirectly. LK
has stimulated considerable interest because of its stability,
low cost and facility for oral administration3–8. However,
thrombotic disease is usually an acute illness for which oral
administration is unsuitable because of issues with bioavail-
ability and slow rate of onset9. Therefore, an injectable
formulation of LK is desirable but brings with it the potential
for antigenicity, immunogenicity and anaphylactic reactions.
One way to reduce these problems is to introduce structural
modiﬁcations to LK which do not compromise its bioactivity
and resistance to degradation.
Pegylation is a well-developed process that can be applied
to therapeutic proteins to enhance their pharmacological
activity, increase their half-life, improve their safety and
tolerability, reduce their immunogenicity, antigenicity and
toxicity and ultimately lead to increased patient compliance
and quality of life10. Methoxy PEGs (mPEGs) are amphiphilic
polymers made up of repeating ethylene oxide subunits with a
methoxy group at one end and a terminal hydroxyl group that
can be chemically activated at the other11. They are available
in a variety of conﬁgurations and molecular weights and can
be linear or branched10,12. Succinimidyl carbonate derivatives
of mPEGs (mPEG-SCs) were recently introduced for mod-
iﬁcation and cross-linking of proteins and preparation of high
molecular weight polymers.
In this study, the pegylation of LK using different reaction
conditions and mPEG-SCs of different molecular weight
was investigated and the ﬁbrinolytic and thrombolytic activ-
ities of the pegylated LKs were determined both in vitro and
in vivo.Figure 1 Isolation and puriﬁcation of crude LK. (a) Size exclusion ch
polymer; peak B has strong ﬁbrinolytic activity. (b) Cation exchange
and protective additive; peak D is puriﬁed LK. (c) SDS-PAGE (10%, w
in the process of puriﬁcation with Akta purify 10. Each band in the2. Materials and methods
2.1. Materials
Crude LK was purchased from Shanghai Guoyuan Bio-tech
Co., Ltd. (Shanghai, China). mPEG-SCs with molecular
weights of 5000, 10,000 and 20,000 (mPEG-SC5000, mPEG-
SC10,000 and mPEG-SC20,000, respectively) were purchased
from Jenkem Technology (Beijing, China). An SDS-PAGE
Test Kit was obtained from Beijing Cellchip Biotechnology
Co., Ltd. and SDS-PAGE protein standards were purchased
from HOUBIO Tech. Co., Ltd. (Hong Kong). Other standard
proteins were purchased from the National Institute for Food
and Drug Control. All other reagents and chemicals were of
analytical grade and used as received.2.2. Isolation and puriﬁcation of LK
Crude LK powder was dissolved in 100 mM sodium phos-
phate at a concentration of 10 mg/mL. Size exclusion chro-
matography was then performed using the Akta Purify 10
system (GE Company) with a Superdex 75 (HiLoad Superdex
75, 16/60) column and a mobile phase of 50 mM PBS, 150 mM
NaCl (pH 7.2) at a ﬂow rate of 0.8 mL/min. Detection was by
UV absorption at 280 nm. Two peaks (A and B) were
observed in the size exclusion chromatogram (Fig. 1a) of
which one (peak B) possessed strong ﬁbrinolytic activity (see
Section 2.5). Subsequently the fraction responsible for peak B
was subjected to cation exchange chromatography using the
same system but equipped with a Hi Trap DEAE FF column
(5 mL). Binding was performed with 50 mM PBS (pH 7.2)
after which elution involved a linear gradient over 60 min with
50 mM PBS, 1 M NaCl (pH 7.2) at a ﬂow rate of 1 mL/min.
Detection was again by UV absorption at 280 nm13–17. The
cation exchange chromatogram (Fig. 1b) also showed two
peaks (C and D) of which one (peak D) showed strong
ﬁbrinolytic activity. Molecular weights of the componentsromatogram of crude LK. Peak A is some high-molecular weight
chromatogram of peak B. Peak C is some low-molecular polymer
/v) of the crude LK and compounds responsible for the four peaks
SDS-PAGE gels corresponds to each fraction.
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polyacrylamide gradient gel with standard proteins as markers
(Fig. 1c). Finally, the crude and puriﬁed LK were examined by
HPLC (Fig. 2) using the following conditions: Column G-450
(250 mm 4.6 mm, 5 mm, Agilent); mobile phase 130 mM
NaCl, 20 mM PBS (pH 5.0); ﬂow rate 1 mL/min; detection
wavelength 280 nm; injection volume 20 mL.2.3. Optimization of the pegylation reaction
2.3.1. Basic procedure
The reaction takes place between the primary amino group of LK
and the terminal carboxylic group of mPEG-SC in a buffer
solution (Scheme 1). Puriﬁed LK (3 mg) was mixed with mPEG-
SC in a molar ratio of 1:25 in 6 mL 50 mM PBS (pH 7.0) at 4 1C.
After 3 h, the reaction was stopped by adding 11 mg/mL
glycine10,18. All products were subjected to ultraﬁltration through
a membrane of MW 30,00019 after which solutions were
lyophilized for 48 h to obtain modiﬁed LKs. Starting materials
and pegylated products were examined by HPLC to calculate the
extent of pegylation according to the following equation19:
Extent of pegylation ð%Þ ¼
ð1residual peak area of LK after modification=peak area
of LK before modificationÞ  100% ð1ÞFigure 2 HPLC chromatograms of (a) crude LK and (b) puriﬁed
LK on a G-450 column (Agilent) using a mobile phase of 130 mM
NaCl, 20 mM PBS (pH 5.0) at a ﬂow rate is 1 mL/min and
detection at 280 nm. The main peak due to LK is at 12.37 min; the
peaks of impurities in (a) elute at 9.22, 10.06 and 12.16 min,
respectively.
Scheme 1 Pegylated modiﬁca2.3.2. Effect of buffer pH
In this study, 3 mg of puriﬁed LK was mixed with mPEG-
SC5000, mPEG-SC10,000 or mPEG-SC20,000 at a molar ratio of
1:5 in 6 mL 50 mM PBS with pH 6.0, 7.0, 8.0 or 9.0 at
4 1C20–22. The reaction was stopped after 3 h and products
isolated as described above.
2.3.3. Effect of reaction time
The reaction was carried out as described in Section 2.3.2 with
buffer pH of 8.0. The reaction was stopped after 1, 2, 3, 4, 5
and 6 h and products from 0.5 mL samples were isolated.
2.3.4. Effect of reaction temperature
The reaction was as described in Section 2.3.2 with buffer pH
of 8.0 and reaction temperatures of either 0, 4 or 25 1C and
products isolated.
2.3.5. Effect of molar ratio
The reaction was as described in Section 2.3.2 with buffer pH
8.0 and the LK:mPEG-SC molar ratio either 1:3, 1:4, 1:5, 1:10,
1:15, 1:20, 1:25 or 1:30 and products isolated.
2.4. Fibrinolytic activity of LK-mPEG-SC in vitro
In vitro ﬁbrinolytic activity was measured using the method of
Asturp and Mullertz23 and urokinase as standard. Protein
concentration of each enzyme solution was determined by the
method of Lowry with BSA as standard. The ﬁbrin agarose
plate contained 120 mg agarose, 40 mg bovine plasma ﬁbrino-
gen and 7 mg thrombin. The clot was allowed to form at room
temperature for 1 h after which 10 mL of each sample was
carefully transferred onto a plate and incubated for 18 h at
37 1C24,25. The diameter of the lytic circle divided by the
protein concentration (X) was used to calculate ﬁbrinolytic
activity (Y) using the equation Y¼12,737ln Xþ8614.5,
R¼0.997 based on the urokinase standard.
2.5. Fibrinolytic activity of LK-mPEG-SC5000 in vivo
Solutions of puriﬁed LK and LK-mPEG-SC5000 made under
optimal conditions were prepared at a concentration of 5
mg/mL. A total of 18 male mice (weight 2075 g) were
randomly assigned to three groups (n¼6) to receive intraper-
itoneal (i.p.) injections of saline (control) or 25 mg/kg puriﬁed
LK or 25 mg/kg LK-mPEG-SC5000 24 h and 1 h before
and 24 h and 48 h after an i.p. injection of carrageenan
(20 mg/kg)26,27. Carrageenan causes the tail ends of mice to
become black due to its thrombolytic activity. At 72 h after the
carageenan injection, the length of the black part of the tails of
each mouse (the thrombus length) was measured and the
average taken as the measure of the thrombotic effect. The
in vivo study was approved by the Animal Care Ethics
Committee of Institute of Materia Medica.tion of LK by mPEG-SC.
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3.1. Isolation and puriﬁcation of LK
Fig. 1a shows the two peaks in the size exclusion chromato-
gram of crude LK. Fig. 1b shows the two peaks in the cation
exchange chromatogram of peak B. The compound respon-
sible for peak D showed strong ﬁbrinolytic activity and was
isolated as puriﬁed LK.
Crude LK and the components responsible for peaks A,
B, C and D in the puriﬁcation process were examined by
SDS-PAGE. As shown in Fig. 1c, crude LK migrated as
several bands, the four main ones having molecular weights
of approximately 105, 35, 27 and 20 kDa. Size exclusion
chromatography showed peak A to be a single protein with
a high molecular weight of about 105 kDa whereas peak B
showed three bands with molecular weights of 35, 27 and
20 kDa. As the effective molecular weight of crude LK was
given as 25–45 kDa, the results of SDS-PAGE are consistent
with the ﬁbrinolytic test, peak A being some polymerized
derivative. SDS-PAGE of peaks C and D in the cation
exchange chromatogram of peak B revealed peak C
migrated as one band with a molecular weight of about
20 kDa while peak D migrated as two bands with molecular
weights of about 27 and 35 kDa. Peak C with little or no
ﬁbrinolytic activity is probably a proteinaceous preservative
agent whereas peak D with strong ﬁbrinolytic activity and a
molecular weight consistent with that of pure LK was
regarded as the puriﬁed sample.
As regards the HPLC study, crude LK gave a single large
peak at 12.95 min accompanied by several impurity peaks with
retention times of 9.22, 10.06 and 12.16 min (Fig. 2a). Puriﬁed
LK, on the other hand, showed the same large peak (this time
at 12.38 min) with no impurity peaks witnessing to the efﬁcacy
of the puriﬁcation process.Figure 3 HPLC chromatograms of (a) puriﬁed LK, (b) mPEG-
SC20,000 and (c) the pegylated product using the same conditions
as in the Fig. 2 caption. The peak due to LK is at 12.38 min, the
peak due to mPEG-SC20,000 is at 13.22 min and the pegylated
product has new peaks at 9.62 min and 10.34 min.3.2. Optimal pegylation conditions
Puriﬁed LK, mPEG-SC20,000 and the pegylated product were
examined by HPLC. As shown in Fig. 3, the peak of puriﬁed
LK is again at 12.38 min (Fig. 3a) whereas the peak of
mPEG-SC20,000 elutes at 13.22 min (Fig. 3b). Both these
peaks are present in the HPLC chromatograph of the
pegylated product (Fig. 3c) along with two new peaks at
9.62 and 10.34 min presumably resulting from a compound
arising from a 1:1 reaction and one from more extensive
pegylation28.
The effect of pH on the pegylation reaction (Fig. 4a)
shows that higher pH increases the extent of reaction but
decreases protein stability. Pegylation occurred most rapidly
at pH 8.0 with LK-mPEG-SC5000, LK-mPEG-SC10,000 and
LK-mPEG-SC20,000 producing 51.35%, 42.04% and 30.22%
reaction respectively. Stability of LK was not compromised
below pH 8.0 and was used in all subsequent reactions.
The effect of reaction time on pegylation is shown in
Fig. 4b. Over the ﬁrst 3 h, the extent of reaction was relatively
constant but increased to some extent in the period 3–5 h.
After 5 h, the extent of reaction decreased possibly due to
protein instability. On this basis, 5 h was considered to be the
optimum duration of reaction.As regards temperature, Fig. 4c shows that pegylation
occurred to the greatest extent at 0 1C and to a lesser extent
at the higher temperatures. Thus 0 1C was chosen as the
optimum reaction temperature.
Figure 4 Effect of buffer pH, reaction time, reaction temperature and molar ratio (mPEG-SC to LK) on extent of pegylation. Puriﬁed
LK was reacted separately with mPEG-SC5000, mPEG-SC10,000 or mPEG-SC20,000 at (a) different pHs (6.0–9.0), (b) different reaction
times (1–6 h), (c) different reaction temperatures (0, 4 and 25 1C) and (d) different molar ratios of LC:mPEG-SC (1:3 to 1:30). The extent
of reaction (%) was determined by HPLC.
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pegylation increased with increasing LK:mPEG-SC ratio
reaching a maximum at a value of 1:25 and declining at a
ratio of 1:30. This indicates mPEG-SC actually impedes the
reaction when present at very high concentrations. Based on
this result, a molar ratio of 1:25 was chosen as the optimum
reaction molar ratio.
3.3. Fibrinolytic activity of LK-mPEG-SC in vitro
The lytic circles resulting from the ﬁbrinolytic activities of
crude LK, puriﬁed LK, LK-mPEG-SC5000, LK-mPEG-
SC10,000 and LK-mPEG-SC20,000 are shown in Fig. 5 and
correspond to values (in U/mg protein) of 16,000, 19,995,
12,426, 11,114 and 9869, respectively. The increase in
ﬁbrinolytic activity from crude to puriﬁed LK shows
puriﬁcation achieves the desired result. However, compar-
ison of the ﬁbrinolytic activity of the pegylated products
shows that the activities of all products are lower than that
of puriﬁed LK although the values are not signiﬁcantly
different. Despite the trend for pegylation to decrease
in vitro ﬁbrinolytic activity, this may not appertain
in vivo because of the longer circulation half life of PEGmodiﬁed LK. Interestingly, since LK-mPEG-SC5000 has
the highest ﬁbrinolytic activity it appears the higher
molecular weight mPEG-SCs hinder the ﬁbrinolytic
activity of LK.
3.4. Fibrinolytic activity of LK-mPEG-SC5000 in vivo
Carrageenans are a family of linear sulfated polysaccharides
extracted from red seaweeds. Hu et al.29 found that carragee-
nan can be used to establish a mouse thrombolytic model
involving blackening of the tail due to local inﬂammation and
endothelial cell damage. As the optimal condition of pegyla-
tion was proved to be as follows: pH 8.0, reaction time of 5 h,
reaction temperature of 0 1C, molar ratio of mPEG-SC to LK
of 1:25, PEG MW of 5000, we selected the optimal condition
to develop pegylated LK and evaluated the ﬁbrinolytic activity
of LK-mPEG-SC5000 in vivo. As shown in Fig. 6 and Table 1,
the incidence of thrombosis and thrombus length in the groups
receiving puriﬁed LK and LK-mPEG-SC5000 was signiﬁcantly
less than in the control group (Po0.01). In addition, the
incidence of thrombosis and thrombus length in the LK-
mPEG-SC 5000 group was signiﬁcantly less than in the LK
group (Po0.05) indicating that the pegylated product is more
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efﬁcacy, the tails of mice in the LK-mPEG-SC5000 group were
lighter in color than in both the puriﬁed LK and controlFigure 6 Representative tails from mice 72 h after an intraper-
itoneal injection of carrageenan (20 mg/kg) and administration of
(A) normal saline, (B) puriﬁed LK and (C) LK-mPEG-SC5000.
Figure 5 In vitro ﬁbrinolytic activity (lytic circles) of crude LK,
puriﬁed LK, LK-mPEG-SC5000 (5 kDa), LK-mPEG-SC10,000
(10 kDa) and LK-mPEG-SC20,000 (20 kDa) on ﬁbrin plates. All
enzymes were dissolved in 50 mM PBS (pH 7.0) at a ﬁnal
concentration of 0.2 mg/mL, applied at a volume of 10 mL and
incubated at 37 1C for 18 h. Urokinase (UK) was used as standard
at concentrations of (1) 4000 U/mL (2), 8000 U/mL (3), 12,000 U/mL
(4), 16,000 U/mL and (5) 20,000 U/mL.
Table 1 Effect of puriﬁed LK and LK-mPEG-SC5000 on the inc
Group Dosage (mg/kg) Inci
Control – 88
Puriﬁed LK 25 54a
LK-mPEG-SC 5000 25 42
a,b
Thrombus length is expressed as mean7standard deviation.
aPo0.01 for the puriﬁed LK and LK-mPEG-SC5000 groups versus c
bPo0.05 for the LK-mPEG-SC5000 group versus the puriﬁed LK grgroups which were dark black in color (Fig. 6). The fact that
pegylated LK has a higher molecular weight than LK
presumably protects it from metabolic clearance and masks
its immunogenic sites10. Whether pegylated LK is in fact less
antigenic, immunogenic and anaphylactic than LK will be the
subject of a future study.4. Conclusions
The conditions for the successful pegylation of LC by mPEG-
SC have been optimized and shown to produce a product with
strong ﬁbrinolytic and thrombolytic activities both in vitro and
in vivo. The product produced from mPEG-SC5000 is a novel
thrombolytic agent that may be clinically useful in the
treatment of acute thrombotic disease. The results of this
study provide the foundation for further research into the
formulation of an injectable LK for human use.
Acknowledgment
This research was supported by the National Nature Science
Foundation of China (No. 30873168) and the Chinese Min-
istry of Education (No. 20101106110031).
References
1. Cong YW, Li Y, Chen JP. The advance of lumbrokinase. Chin J
Biochem Pharm 2001;21:159–62.
2. Wang F, Wang C, Li M. Puriﬁcation, characterization and
crystallization of a group of earthworm ﬁbrinolytic enzymes from
Eisenia fetida. Biotechnol Lett 2003;25:1105–9.
3. Wang F, Wang C, Li M. Crystal structure of earthworm
ﬁbrinolytic enzyme component B: a novel, glycosylated two-
chained trypsin. J Mol Biol 2005;348:671–85.
4. Nakajima N, Mihara H, Sumi H. Characterization of potent
ﬁbrinolytic enzymes in earthworm, Lumbricus rubellus. Biosci
Biotechnol Biochem 1993;57:1726–30.
5. Hrzenjak T, Popovic M, Bozic T, Grdisa M, Kobrehel D, Tiska-
Rudman L. Fibrinolytic and anticoagulative activities from the
earthworm Eisenia foetida. Comp Biochem Physiol B Biochem Mol
Biol 1998;119:825–32.
6. Tang Y, Zhang J, Gui L, Wu C, Fan R, Chang W, et al.
Crystallization and preliminary X-ray analysis of earthworm
ﬁbrinolytic enzyme component A from Eisenia fetida. Acta
Crystallogr D Biol Crystallogr 2000;56:1659–61.
7. Sugimoto M, Nakajima N. Molecular cloning, sequencing, and
expression of cDNA encoding serine protease with ﬁbrinolytic activity
from earthworm. Biosci Biotechnol Biochem 2001;65:1575–80.
8. Wu C, Li L, Zhao J, Fan Q, Tian WX, He RQ. Effect of alpha2M
on earthworm ﬁbrinolytic enzyme III-1 from Lumbricus rubellus.
Int J Biol Macromol 2002;31:71–7.idence and extent of thrombosis in mice (n¼6).
dence of thrombosis (%) Thrombus length (mm)
15.870.9
11.871.2 a
9.971.0 a,b
ontrol.
oup.
Preparation of pegylated lumbrokinase and an evaluation of its thrombolytic activity both in vitro and in vivo 1299. Lu L, Xu YN, Liu J, Qian M, Wang J. Clinical effect of injective
lumbrokinase. Acta Univ Med Nanjing 2007;27:1326–7.
10. Jo YW, Youn TS, Lee SH, Kim BM, Kang SH, Yoo MH, et al.
Long-acting interferon-a 2a modiﬁed with a trimer-structured
polyethylene glycol: preparation, in vitro bioactivity, in vivo
stability and pharmacokinetics. Int J Pharm 2006;309:87–93.
11. Pascal B, Wolfgang B. Polyethylene glycol-conjugated pharma-
ceutical proteins. Pharm Sci Technol Today 1998;1:352–6.
12. Raut S, Bhadoriya SS, Uplanchiwar V, Mishra V, Gahane A, Jain
SK. Lecithin organogel: A unique micellar system for the delivery
of bioactive agents in treatment of skin aging. Acta Pharm Sin B
2012;2:8–15.
13. Caserman S, Kusterle M, Kunstelj M, Milunovic T, Schiefermeier
M, Jevsevar S, et al. Correlations between in vitro potency of
polyethylene glycol-protein conjugates and their chromatographic
behavior. Anal Biochem 2009;389:27–31.
14. Foser S, Schacher A, Weyer KA, Bruqqer D, Dietel E, Marti S,
et al. Isolation, structural characterization, and antiviral activity
of positional isomers of monopegylated interferon alpha-2a
(PEGASYS). Protein Expr Purif 2003;30:78–87.
15. Yao WB, Yang XB, Wu WT. Primary analytical study on the
PEG-modiﬁed rhIFNa-2b. Chin J Biochem Pharm 2003;24:274–6.
16. Garg G, Shah JP, Kumar S, Bryant CS, Munkarah A, Morris RT.
Ovarian and uterine carcinosarcomas: a comparative analysis of
prognostic variables and survival outcomes. Int J Gynecol Cancer
2010;20:888–94.
17. Xiong C, Wu H, Wei P, Pan M, Tuo Y, Kusakabe I, et al. Potent
angiogenic inhibition effects of deacetylated chitohexaose sepa-
rated from chitooligosaccharides and its mechanism of action
in vitro. Carbohydr Res 2009;344:1975–83.
18. Tsui SM, Lam WM, Lam TL, Chong HC, So PK, Kwok SY,
et al. Pegylated derivatives of recombinant human arginase
(rhArg1) for sustained in vivo activity in cancer therapy:preparation, characterization and analysis of their pharmacody-
namics in vivo and in vitro and action upon hepatocellular
carcinoma cell (HCC). Cancer Cell Int 2009;9:9.
19. Ying GQ, Yi Y, Shi LE, Wang S, Hu MS. Preparation and
properties of earthworm ﬁbrinolytic enzyme modiﬁed with mPEG.
J Chem Eng Chin Univ 2005;19:527–31.
20. Xu J, Ni DM, Zhang ZL. Preliminary study on chemical
modiﬁcation of interferon-b by polyethylene glycol. Prog Micro-
bial Immunol 2004;32:30–3.
21. Yang NF, Huang J, Xu FH. Optimization of condition for
modiﬁcation of recombinant human interferon-a1b with poly-
ethylene glycol. Chin J Biologicals 2008;21:329–32.
22. Liu LJ, Zhao L, Zhu X. Chemical modiﬁcation of rhIFNa2b with
activated polyethylene glycol. Chin J Biologicals 2001;14:210–2.
23. Astrup T, Mullertz S. The ﬁbrin plate method for estimating
ﬁbrinolytic activity. Arch Biochem Biophys 1952;40:346–51.
24. Wang P, Chen J, Chen HB. Puriﬁcation and its thrombolytic and
hematolytic effect of nattokinase in vitro. Chin Pharm J
2005;40:1669–71.
25. Shen MH, Kim JS, Sapkota K, Park SE, Choi BS, Kim CS, et al.
Puriﬁcation, characterization, and cloning of ﬁbrinolytic metallo-
protease from Pleurotus ostreatus mycelia. J Microbiol Biotechnol
2007;17:1271–83.
26. Ding SW, Wei LB, Shi HX. Effects of spirit on formation of
thrombus in rats’ tails caused by carrageenan. Chin Prev Med
2004;5:161–3.
27. Dinarello CA. Modalities for reducing interleukin 1 activity in
disease. Immunol Today 1993;14:260–4.
28. Zalipeky S, Lee C. Poly (ethylene glycol) chemistry: biotechnical
and biomedical applications. New York: Plenum Press; 1999. p.
347–70.
29. Hu SJ, Tian QL, Gu JW. A new in vivo animal model of
thrombosis formation. J Fourth Milit Med Univ 1993;14:69.
